Introduction {#S0001}
============

Cardiomyopathies are heterogeneous heart muscle diseases that commonly have a genetic cause \[[@CIT0001], [@CIT0002]\]. Whereas hypertrophic cardiomyopathy (HCM) and left ventricular non-compaction cardiomyopathy (LVNC) are classified as genetic forms according to the American Heart Association, dilated cardiomyopathy (DCM) is familial in about one third of patients. The heterogeneous nature of the cardiomyopathies can be seen at the clinical and the genetic level \[[@CIT0001], [@CIT0002]\]. In HCM, the known disease genes may account for genetic causation in only about 50--60% of patients \[[@CIT0001], [@CIT0002]\]. Presumably additional disease genes exist. Recent studies also changed our earlier view of HCM as a solely sarcomeric and DCM as a solely cytoskeletal disorder. It has been shown that considerable overlap of disease-causing genes exists between the main phenotypically distinct forms of cardiomyopathy \[[@CIT0003], [@CIT0004]\]. Moreover, mutations in certain genes may cause very variable phenotypes \[[@CIT0003], [@CIT0004]\].

Mutations in Z-disk associated proteins have been linked to cardiomyopathy \[[@CIT0002], [@CIT0005]\]. The cardiac-specific protein nebulette, encoded by *NEBL*, is a good candidate, since the protein aligns thin filaments and connects them to the Z-disk. Nebulette belongs to the nebulin family of actin-binding proteins that are important in myofibrillogenesis \[[@CIT0006], [@CIT0007]\] and assembly of the Z-line \[[@CIT0008]\]. Nebulette also interacts with filamin C \[[@CIT0009]\], myopalladin \[[@CIT0010]\], α-actinin 2 \[[@CIT0007]\], and tropomyosin and troponin T \[[@CIT0011], [@CIT0012]\]. The key role of *NEBL* is further supported by the recent generation of transgenic mice overexpressing *NEBL* mutations in the heart and showing severe cardiac phenotypes \[[@CIT0013]\].

We therefore selected *NEBL* as a candidate gene in patients with cardiomyopathies and systematically analyzed the gene in three well-characterized cohorts of patients with HCM, DCM, and LVNC.

Material and methods {#S0002}
====================

Patients {#S20003}
--------

We studied 389 unrelated cardiomyopathy patients with HCM, DCM, or LVNC of mostly European origin. The respective local institutional review boards (IRB) in Berlin, Paris, Prague, Pecs and Padova approved the study and written informed consent was obtained from all participants. The genetic analysis was performed in Berlin (IRB vote number AA/3/01/32 for genetic analysis in cardiomyopathy patients). The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki.

The HCM cohort comprised 217 patients. The patients were managed either in Paris (96 patients), in Padova (26 patients) or in Prague (95 patients). The diagnosis of HCM was made according to the established criteria as described by us in detail previously \[[@CIT0014], [@CIT0015]\]. The DCM cohort included 148 patients. The patients were managed either in Paris (114 patients; 65 familial and 49 sporadic) or in Berlin (34 familial patients). Diagnosis of DCM was made according to the established criteria as used and described previously \[[@CIT0016], [@CIT0017]\]. The LVNC cohort comprised 24 patients managed in Pecs. Relatives of patients with identified mutation were recruited after the initial genetic analysis and subsequently selected from their families. Diagnosis of LVNC was based on the criteria proposed by Petersen *et al*. \[[@CIT0018]\]. The control cohort A comprised 320 sex-matched unrelated individuals (European origin) without cardiomyopathy. The second control cohort B included 192 sex-matched blood donors (European origin) without heart disease. Further information about the cohorts can be found in the Supplemental methods.

Genetic analysis {#S20004}
----------------

Genomic DNA was isolated using standard methods. Primer pairs were used to amplify the 28 coding exons of *NEBL* with flanking intronic sequences according to Arimura *et al*. \[[@CIT0019]\] based on the published sequence (GenBank accession number *NM_006393.2*). Polymerase chain reaction amplifications were performed using standard protocols (available on request). The amplicons were analyzed by direct sequencing using ABI Big Dye Terminator chemistry and run on an ABI 3100 Avant device (Applied Biosystems, Darmstadt, Germany) as per the manufacturer\'s instructions. Detected variants in a sample were confirmed at least in two independent PCRs and sequencing runs. Sequencher software version 4.8 (Gene Codes, Ann Arbor, MI, USA) or PhredPhrap/Consed free Softs was used to facilitate data analysis and mutation identification followed by visual inspection of individual sequencing traces. Genetic variants were annotated according to the cDNA and protein reference sequence (Ensembl ID *ENST00000377122* and UniProtKB/Swiss-Prot *O76041*).

We further analyzed the detected variants by checking the presence or absence of these variants in large population-based databases (dbSNP and Exome Sequencing Project/ESP5400 dataset) and the possible impact of the amino acid substitution. Further information about the bioinformatic analysis can be found in the Supplemental Methods. Briefly, the significance of the identified variants was assessed by considering the conservation of the affected amino acid, the nature and location of the change, its rarity assessed in own controls and population-based datasets, and cosegregation in the family when available.

Results {#S0005}
=======

*NEBL* mutations {#S20006}
----------------

We sequenced *NEBL* in 389 cardiomyopathy patients and identified 20 different genetic variants ([Figure 1](#F0001){ref-type="fig"}). Fourteen variants were detected in different frequencies (from 1% to 31%) and were regarded as polymorphisms ([Figure 1 A](#F0001){ref-type="fig"} and see also Supplemental results and [Supplemental Table SI](#T0003){ref-type="table"}). In contrast, six variants were detected in 1 patient each: p.H171R, p.A175T, p.Q581R, p.I652L, p.S747L, and p.P916L (with the exception of p.A175L, which was detected in two unrelated patients) ([Table I](#T0001){ref-type="table"}). These were regarded as possibly disease-associated mutations because of the following facts. All six were heterozygous missense mutations ([Supplemental Figure S1](#F0005){ref-type="fig"}); none was detectable in 640 control alleles. Two mutations were not annotated in dbSNP (p.H171R, p.Q581R); we deposited two (p.A175T, p.S747L) ([Table I](#T0001){ref-type="table"}). The mutations p.I652L and p.P916L were subsequently annotated in dbSNP with low allelic frequencies of 0.3% and 0.08%, respectively ([Table I](#T0001){ref-type="table"}). While four mutations were absent from the ESP5400 dataset (European Americans), two (p.A175T and p.I652L) occurred at a very low frequency of \< 0.01%. Five amino acid substitutions altered a non-conserved residue (the exception was p.I652L). Two independent mutation analysis tools predicted damaging effects for the six mutations (either PolyPhen2 and/or Mutation Taster; see Supplemental methods).

![Localization of the mutations and other variants in the nebulette gene and protein. **A** -- Distribution of detected variants in *NEBL*. In the schematic diagram, gray blocks symbolize the 28 exons of the gene. Very rare variants (possible disease-associated mutations) are indicated as black arrows above their exonic location. Other more frequent synonymous and non-synonymous variants are indicated by small gray arrows below their exonic location. **B** -- Localization of the identified mutations in the nebulette protein. In the schematic diagram, gray blocks symbolize different protein domains. Nebulette consists of an N-terminal acidic glutamic acid-rich domain, 23 central nebulin-like repeats (NLR), a serine-rich linker domain, and a C-terminal Src homology 3 (SH3) domain. Binding partners and interactions are shown below. The six possible mutations identified by us are denoted by long black arrows above the diagram, whereas mutations identified by Purevjav *et al*. \[[@CIT0013]\] are denoted by small black arrows below the diagram. Notably, some of the mutations are close together, e.g. affecting the same NLR in two cases (schematic representations and interactions according to \[[@CIT0006], [@CIT0008], [@CIT0029]\])](AMS-12-27358-g001){#F0001}

###### 

Possible mutations in *NEBL*

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Exon   DNA change   AA change   Affected domain   Non-consv. change   Conserved in orthologs   PolyPhen2/Mutation Taster analysis   dbSNP ID                                      EA allelic\
                                                                                                                                                                                    frequency, ESP (%)
  ------ ------------ ----------- ----------------- ------------------- ------------------------ ------------------------------------ --------------------------------------------- --------------------
  6      c.512A\>G    p.H171R     NLR 4             Yes                 Highly                   Prob. damaging/disease causing       Novel                                         0

  6      c.523G\>A    p.A175T     NLR 5             Yes                 Mammals                  Benign/disease causing               rs71541562[1](#TF0001){ref-type="table-fn"}   0.01

  17     c.1742A\>G   p.Q581R     NLR 16            Yes                 Mammals                  Prob. damaging/polymorphism          Novel                                         0

  19     c.1954A\>C   p.I652L     NLR 18            No                  Highly                   Benign/disease causing               rs200756166                                   0.01

  22     c.2240C\>T   p.S747L     NLR 21            Yes                 Highly                   Prob. damaging/disease causing       rs71578957[1](#TF0001){ref-type="table-fn"}   0

  26     c.2747C\>T   p.P916L     Linker            Yes                 Mammals                  Poss. damaging/disease causing       rs143149169                                   0
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AA -- amino acid, Non-consv. change -- substituted residues show different physiochemical properties, PolyPhen2 -- sequence/structure-based amino acid substitution prediction method, NLR -- nebulin-like repeat domain of nebulette, dbSNP -- SNP database (build 135), ESP -- Exome Sequencing Project of the NHLBI (dataset ESP5400 2012; determined in 3510 European American individuals), prob. -- probably, poss. -- possibly, EA -- European American.

deposited by us.

Mutation p.P916L is located in the N-terminal serine-rich linker region; the other five mutations are located in the central nebulin-like repeats (NLRs). These are important actin-binding modules of the protein ([Figure 1 B](#F0001){ref-type="fig"}). Alignment of sequences surrounding mutations from different orthologs (from chimpanzee to fish) showed very high conservation of the residue through evolution for three mutations (p.H171R, p.I652L, p.S747L) to high conservation for the other three mutations ([Figure 2 B](#F0002){ref-type="fig"}). Alignment of the 23 NLRs showed that three mutations (p.Q581R, p.I652L, p.S747L) are located in or close to the two common consensus motifs (PEIXRXK box and SDXXYK box) in these domains ([Figure 2 A](#F0002){ref-type="fig"}). The amino acids glutamine (p.Q581R) and isoleucine (p.I652L) are also conserved in different nebulette NLRs.

![Conservation of the identified possible mutations p.H171R, p.A175T, p.Q581R, p.I652L, p.S747L, and p.P916L. **A** -- Alignment of the 23 copies of nebulin-like repeats (NLR) present in human nebulette (according to Millevoi *et al*. \[[@CIT0030]\]) with mutations p.H171R, p.A175T, p.Q581R, p.I652L, p.S747L (small boxes). The NLRs are modules of about 35 residues present in all members of the nebulin protein family. They are characterized by the sequence motif SDXXYK (open box). NLR 15 to 22 additionally share a conserved motif (PEIXRXK box at their N-termini). The mutations are located in or close to these consensus motifs. The amino acids glutamine (p.Q581R) and isoleucine (p.I652L) are also conserved in different nebulette NLRs (as shown by bold letters). **B** -- Alignment of orthologs from 16 different species (from mammals and birds to fish). The altered amino acid and flanking residues are displayed in single-letter code. Bold letters mean conservation. Mutated residue in the human sequence is underlined](AMS-12-27358-g002){#F0002}

Mutations p.H171R and p.I652L were found in 2 HCM patients. Further, the mutations p.Q581R and p.S747L were detected in 2 familial DCM patients, while the mutation p.A175T was detected in 2 unrelated patients with DCM. One LVNC patient carried p.P916L. Overall, this occurrence has a frequency of 1.8% (7/389). Mutation screening performed previously on several other cardiomyopathy genes in these patients was negative (details see below). As commonly observed in cardiomyopathy, the small size of the families and the age-related incomplete penetrance only allowed cosegregation analysis in the families. The pedigrees are shown in alphabetical order in [Figure 3](#F0003){ref-type="fig"}. The clinical data of these patients are summarized in [Table II](#T0002){ref-type="table"}.

![Pedigrees of the families. Squares indicate males, circles females. Open symbols represent unaffected subjects and solid symbols affected individuals according to clinical examinations; shaded symbols represent individuals with borderline status; question marks represent individuals with unknown status where no clinical data were available; and slanted bars represent deceased individuals. The presence or absence of an *NEBL* mutation is indicated by a "+" or "--" symbol, respectively. No such symbol indicates that no DNA was available for analysis. An arrow denotes the proband](AMS-12-27358-g003){#F0003}

###### 

Clinical data of the probands carrying possible *NEBL* mutations

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Family   Proband   Gender   Diagnosis       Mutation                                   Age at diagnosis   LVEDD\   EF\   IVS\      PWT\     ICD   Arrhythmias (ECG)           NYHA\
                                                                                                            \[mm\]   (%)   \[mm\]    \[mm\]                                     class
  -------- --------- -------- --------------- ------------------------------------------ ------------------ -------- ----- --------- -------- ----- --------------------------- ---------
  A        A: II-6   Male     Sporadic HCM    p.H171R                                    53                 43       75    18        13       No    SR, negative T waves        III

  B        B: II-3   Female   Familial HCM    p.I652L[1](#TF0002){ref-type="table-fn"}   14                 62       26    26        14       Yes   nsVT, sVT                   III

  C        C: II-4   Male     Familial DCM    p.A175T                                    45                 78       15    No hyp.   nd       Yes   nsVT, AF                    III

  D        D: II-1   Male     Familial DCM    p.Q581R                                    46                 69       48    13        nd       No    sVT                         II--III

  E        E: II-1   Female   Sporadic DCM    p.A175T                                    48                 54       40    nd        nd       No    SR, cLBBB                   II

  F        F: II-1   Male     Familial DCM    p.S747L                                    49                 72       35    10        nd       No    SR, LVH, negative T waves   II

  G        G: II-1   Male     Sporadic LVNC   p.P916L                                    41                 66       30    10        10       Yes   nsVT                        II--III
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ICD -- implantable cardioverter/defibrillator, LVEDD -- left ventricular end diastolic diameter, EF -- ejection fraction, IVS -- intraventricular septal thickness, PWT -- posterior wall thickness, s/nsVT -- sustained or non-sustained ventricular tachycardia, cLBBB -- complete left bundle branch block, AF -- atrial fibrillation, hyp. -- hypertrophy, SR -- sinus rhythm, LVH -- signs for left ventricular hypertrophy, nd -- not determined.

Variant of unknown significance (see discussion).

Clinical features in HCM {#S20007}
------------------------

The symptomatic male patient (proband A: II-6 of family A) of Czech origin, carrier of mutation p.H171R, had HCM since the age of 53 years. He presented with moderate hypertrophy including an interventricular septal thickness (IVS) of 18 mm and posterior wall thickness (PWT) of 13 mm. His sister (A: II-5), 56 years old, was a carrier of the mutation but showed no signs of HCM. All other family members were negative for the mutation and also showed no HCM. Individuals A: II-2, A: II-3, and A: II-4 showed IVS values of 11--12 mm; all were treated for arterial hypertension.

The Italian female patient (proband B: II-3 of family B), carrier of mutation p.I652L, was diagnosed with juvenile HCM with severe hypertrophy at the age of 14 years. She received an implantable cardioverter defibrillator (ICD) because of ventricular tachycardia (further clinical data in the Supplemental Results and [Supplemental Figure S2](#F0006){ref-type="fig"}). Her mother (B: I-2), 69 years old, carried the mutation and showed mild septal hypertrophy. But she was operated on because of calcific aortic stenosis and a bicuspid aortic valve. Her father (B: I-1), aged 74 years, demonstrated HCM with an age of onset at 60 years and later on developed hypertension but did not carry the mutation. Of note, her brother (B: II-2), aged 45 years and a non-carrier of the mutation, showed mild hypertrophy and was treated for hypertension for about 20 years. The 3 children (B: III-1, B: III-2, and B: III-3), aged from 18 to 22 years and each of whom had normal values in echocardiography, also did not carry the mutation. Neither of the above families had mutations in sarcomeric HCM genes (analyzed by DNA resequencing array by us and coworkers \[[@CIT0020]\]).

Clinical features in DCM {#S20008}
------------------------

The 47-year-old German patient (proband II-4 of family C), carrier of mutation p.A175T, had disease onset at the age of 45 years and had severe DCM with a strongly dilated left ventricle and poor LV function (EF 15%). ECG showed atrial fibrillation as well as non-sustained ventricular tachycardia; an ICD was implanted. His twin brother (C: II-3) is also a carrier of the mutation and awaits heart transplantation (TX) because of severe DCM. His female cousin (C: III-1) underwent TX because of DCM but was not available for genetic analysis. The proband has two male children (C: III-2, 19 years old, and C: III-3, 23 years old) who carried the mutation but were as yet disease free. His father (C: I-4) died of heart failure. The symptomatic brother (C: II-6) showed a mildly dilated heart. He was diagnosed with an alcohol-toxic form of DCM because of known long-term excessive alcohol consumption and showed a negative genotype.

The German male patient (proband D: II-1 of family D), aged 52 years and carrier of mutation p.Q581R, had symptoms (including dizziness and dyspnea on exertion) since the age of 46. Holter ECG showed intermittent tachycardia. He has a dilated LV and borderline LV function (48%). His father (D: I-1) died at the age of 52 years because of DCM. His 60-year-old brother (D: II-2) awaits TX. No DNA was available from either. The disease genes *LMNA*, *MYH7*, *ACTC*, *DES*, *PLN*, *MLP*, *TNNC*, *TNNI* were excluded in both probands of families C and D.

The French female patient (proband E: II-1 of family E), carrier of mutation p.A175T, was diagnosed with DCM at the age of 48 years. She showed mild dilatation and diminished LV function (EF 40%). Proband E: II-1 has a sporadic form of DCM; no other family members were affected or were available for genetic analysis.

The French male patient (proband F: II-1 of family F), carrier of mutation S747L and of Syrian origin, showed disease onset at the age of 49 years. He had severe dilatation and poor LV function with an EF of 35%. His father (F: I-1) died at the age of 63 years because of heart failure. No other family members were available for clinical and genetic examination. Important DCM disease genes (*LMNA*, *MYH7*, *ACTC*, *DES*, *SGCD*, *TNNT2*, *PLN*, *MYPN*, and the cardiospecific exon 16 of *VCL*) were excluded in both probands of family E and F.

Clinical features in LVNC {#S20009}
-------------------------

The 47-year-old male patient of Hungarian origin (proband G: II-1 of family G), carrier of mutation p.P916L, has been treated because of DCM and heart failure since the age of 37 years. Echocardiography suggested the presence of hypertrabecularization in the apical region of the left ventricle. Cardiac magnetic resonance imaging (MRI) confirmed LVNC as described in Supplemental results and [Supplemental Figure S3](#F0007){ref-type="fig"}. His 67-year-old mother (G: I-2) and his two children (G: III-1 and G: III-2), 25 and 19 years old, respectively, were negative for the mutation and were unaffected as shown by echo and/or MRI. The proband G: II-1 had been analyzed previously for mutations in 12 known cardiomyopathy genes as described by us \[[@CIT0020]\], and no mutation was found in any of these genes.

Discussion {#S0010}
==========

We identified six novel heterozygous missense mutations in *NEBL* in seven different patients and their families. We excluded known cardiomyopathy genes in these patients, particularly the most frequent HCM disease genes \[[@CIT0014], [@CIT0020]\]. Overall, our data are highly suggestive for disease causation, although without definite proof because of the small size of most families. The presence of six different mutations in seven unrelated cardiomyopathy patients makes the possible explanation of rare polymorphisms highly unlikely. This interpretation is confirmed by the absence of the mutations in a high number of ethnically matched control individuals. Despite the very low frequency of the mutations (\< 1/1000 alleles), we detected the 175 variant in two independent patients from Germany and France. Exome Sequencing Project (ESP) and dbSNP datasets confirmed the rarity/novelty of all mutations, which is a major criterion for pathogenicity in cardiomyopathies with so many "private" mutations \[[@CIT0001], [@CIT0002], [@CIT0004]\]. Norton *et al*. proposed using the ESP dataset as a new resource for guidance in DCM patients \[[@CIT0021]\]. They found an allele frequency of 0.04% as a conservative cut-off point for pathogenic mutations based on their bioinformatic analysis of DCM mutations against the ESP dataset. Using the same approach for *NEBL*, all mutations found by us are below that threshold, confirming their extreme rarity ([Table I](#T0001){ref-type="table"}).

We are aware that a non-synonymous mutation causing a genetic disease increases in evolutionarily highly conserved sites \[[@CIT0022]\]. The affected amino acids of the identified mutations were highly conserved in different species. Interestingly, the conservation could be partially observed in nebulette itself. The mutations at codons 581 and 652 showed this conservation also in the different nebulin-like repeats ([Figure 2 A](#F0002){ref-type="fig"}). Furthermore, the changes were non-conservative; namely, they changed the properties of the residues such as polarity or size, indicating deleterious effects on protein structure.

The localization of the mutations in a functional protein domain underscores a possible pathogenic effect. Notably, five of the identified mutations reside in the nebulin-like repeats, the basic functional units for actin binding. The sixth mutation (p.P916L) is located in the serine-rich linker domain responsible for cellular targeting in the Z-disk (as shown by Panaviene *et al*. \[[@CIT0023]\]). The fact that transgenic animal models expressing human *NEBL* mutations generated by Purevjav *et al*. resembled a cardiomyopathic phenotype strongly enhances the confidence in our results \[[@CIT0013]\]. Finally, the *NEBL* gene that encodes the Z-disk protein, nebulette, is an excellent candidate gene to contribute to heart muscle disease. The fact that *NEBL* is preferentially expressed in the heart makes such speculation more plausible. Furthermore, there are a number of known cardiomyopathy disease genes encoding Z-disk proteins ([Figure 4](#F0004){ref-type="fig"}). This scheme is quite fitting for nebulette.

![Diagram of the overlap of disease genes causing four different cardiomyopathy forms. Thirty-seven genes have been described so far, of which 20 genes cause at least two different forms of cardiomyopathy. Underlined gene symbols encode Z-disk proteins. Of note, all seven Z-disk genes are involved in the pathogenesis of two different cardiomyopathy forms. Conclusively, we have described the Z-disk gene *NEBL* as possibly associated with HCM, DCM and LVNC in this study (data according to \[[@CIT0001]--[@CIT0004]\])](AMS-12-27358-g004){#F0004}

Purevjav *et al*. \[[@CIT0013]\] drew attention to four missense mutations in *NEBL* (p.K60N, p.Q128R, p.G202R, p.A592E). These are also located in the nebulin-like repeats and are in close vicinity to five mutations identified by us affecting the same repeat domain in two cases ([Figure 1 B](#F0001){ref-type="fig"}). They found *NEBL* mutations in two newborn DCM patients (one with endocardial fibroelastosis) and two patients with DCM manifestation in adulthood \[[@CIT0013]\]. We found mutations in familial as well as sporadic cases with DCM and additionally in cases with HCM or LVNC. Furthermore, we identified clinical manifestation of cardiomyopathy mostly in adulthood (the exception was one child with severe HCM). There seems to be a possible relation to age as seen in the probands with NEBL mutations who have an age at diagnosis between 41 and 53 years ([Table II](#T0002){ref-type="table"}).

Relatives without cardiomyopathy often showed a negative genotype, whereas pathological phenotypes co-segregated with an *NEBL* mutation ([Figure 3](#F0003){ref-type="fig"}). However, two individuals, C: III-2, 19 years old, and C: III-3, 23 years old, from family C were mutation carriers without a cardiomyopathy phenotype. This could be attributed to their young age, which is well known to be associated with a low probability of cardiomyopathy expression due to age-related penetrance \[[@CIT0001], [@CIT0004]\]. The unaffected individual A: II-5, a mutation carrier and 56 years old, may be explained by the fact that penetrance increases with age but remains less than 100%, as Watkins *et al*. stated in their review \[[@CIT0004]\]. The clinical significance of the p.I652L variant in family B is puzzling. The mother (B: I-2) showing hypertrophy and aortic stenosis was a carrier of the mutation. However, two relatives with some degree of hypertrophy did not carry the mutation. While individual B: I-1 had an unequivocal HCM, individual B: II-2 showed mild hypertrophy and arterial hypertension and therefore may be regarded as a likely phenocopy (i.e. masquerading as HCM). On the one hand, p.I652L is highly conserved in orthologs and NLRs and quite rare in patients and controls (0.01% according to ESP). On the other hand, it is the only conserved change predicted to be benign by PolyPhen2 and has an allelic frequency of 0.3% according to dbSNP. Taken together, we would classify p.I652L as a variant of unknown significance.

We suggest that *NEBL* mutations may generate cardiomyopathy phenotypes. Thus we must propose mechanisms. Moncman and Wang showed that a targeted disruption of nebulette expression in cardiomyocytes significantly altered myofibril assembly and function \[[@CIT0024]\]. Purevjav *et al*. validated the functional effects of four human *NEBL* missense mutations in detail \[[@CIT0013]\]. They generated transgenic mice with cardiac-restricted overexpression of human wild-type and mutant nebulette, showing a variety of phenotypes and severity *in vivo* ranging from embryonic lethality due to cardiac abnormalities to LV enlargement and diminished LV function at later stages \[[@CIT0013]\]. Effects at the molecular/cellular level were changes in I-band and Z-disk composition and abnormal distribution of mutant nebulette under mechanical stretch. Their findings showed that *NEBL* mutations have strong but different effects on nebulette function itself and the function of interacting proteins depending on the location of the respective mutation. Ram and Blaxall concluded that nebulette may play dual roles as both a structural protein of the Z-disk, and also -- possibly through its binding partners -- as a regulatory protein of signaling pathways \[[@CIT0025]\]. The findings of Purevjav *et al*. suggest that nebulette is required for normal sarcomere genesis and Z-disk stabilization during development and adult function \[[@CIT0013]\].

We were struck by the fact that nearly all Z-disk genes were associated with DCM as well as HCM, as Bos and Ackerman noted \[[@CIT0026]\] (underlined genes in [Figure 4](#F0004){ref-type="fig"}). They pointed out that for Z-disk-mediated cardiomyopathies it is difficult to envision how divergent phenotypes emerge, especially because maladaptive dilatation seems a more plausible phenotypic response than maladaptive hypertrophy, given the role of the Z-disk as a sarcomeric stretch sensor and mechanoreceptor \[[@CIT0026]\]. The divergence in phenotypes may reflect the multiple roles of nebulette in modulating cardiomyocyte stretch-strain with specific structural/cytoskeletal modifications, as Ram and Blaxall proposed \[[@CIT0025]\]. However, there is still a wide knowledge gap between the specific genetic cause and the mechanism producing a specific clinical phenotype \[[@CIT0003]\]. A complete understanding of how underlying mutation and resulting phenotype are connected is still pending for the cardiomyopathies. It is obvious that the ultimate phenotype represents the sum of all the parts: genotype, mutant RNA and protein expression, further genetic variants, and epigenetic influences as well as environmental factors \[[@CIT0003]\]. But we still lack integrated approaches that could elucidate the mechanisms.

There may be some caveats to the interpretation of the present study. First, it is limited by the fact that the families were too small to perform linkage analysis. Cosegregation analysis was possible in four families and produced inconclusive results in one of them. Second, no functional studies were performed. We were therefore cautious with the assignment of true disease causation \[[@CIT0002], [@CIT0021], [@CIT0027], [@CIT0028]\]. However, considering the conservation of the affected amino acid, the nature and location of the change, its absence in controls and the general population, and the reported animal models of related mutations point to a possible significance of five of the identified mutations (as we regard p.I652L as a variant of unknown significance).

It was not possible to screen all known genes associated with cardiomyopathy; so we cannot exclude the possibility that the mutation carriers may be double heterozygotes. This is in particular true for DCM genes, whereas we excluded nearly all HCM genes. However, even greater patient numbers may be necessary to draw more general conclusions about the frequency of *NEBL* mutations in cardiomyopathy patients. Our purpose here was to draw attention to *NEBL*, a gene that we believe warrants much more multidisciplinary research attention.

In conclusion, our data strongly suggest that five different *NEBL* mutations are possibly associated with various cardiomyopathies. Already known for DCM, we herein describe the first possible *NEBL* mutations in HCM and LVNC. Our findings underline the notion that the cardiomyopathies are true allelic diseases. With regard to next generation sequencing methods, *NEBL* may be added to a set of cardiomyopathy genes which now can be quickly analyzed in parallel with a target enrichment approach.
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Patients {#S20015}
--------

In total, 389 unrelated cardiomyopathy patients (HCM, DCM, or LVNC) were evaluated according to the American Heart Association definitions \[[@CIT0031]\]. They were all of European origin (with the exception of the French DCM cohort with 93% Western Europeans). All cohorts were examined using a comparable protocol based on the medical history, physical examination, two-dimensional and M-mode echocardiography, and 12-lead electrocardiogram (ECG), without knowledge of the genetic status. Holter ECG, heart catheterization, angiography, and cardiac magnetic resonance imaging (MRI) were performed in some patients as clinically indicated. Causes of heart disease such as coronary artery disease, myocarditis, severe arterial hypertension, and valvular heart disease were carefully excluded from the present study. All subjects agreed to participate in the study and gave written informed consent. The study was approved by the responsible local institutional review boards in the respective centers.

The diagnosis of HCM was made according to the established criteria. Briefly, the major inclusion criterion was the presence of interventricular septal thickness (IVS) ≥ 13 mm (15 mm if sporadic, 13 mm if familial) in the absence of other known causes of hypertrophy (such as hypertension and aortic stenosis) often accompanied by major ECG abnormalities such as negative T-waves, pathological Q-waves, and left ventricular hypertrophy.

Diagnosis of DCM was made according to the established criteria. The main criteria for DCM were defined as an echocardiographically measured left ventricular ejection fraction (EF) \< 45% and left ventricular end-diastolic diameter (LVEDD) \> 56 mm (or greater than the theoretical value according to age and body surface) in the absence of coronary artery disease. The patients had no systemic hypertension. Familial DCM was diagnosed if another affected relative had proven or highly suspected DCM according to the European guidelines of Mestroni *et al*. \[[@CIT0032]\].

Diagnosis of LVNC was based on established criteria. All included patients showed a thickened LV myocardial wall with a two-layered structure comprising a compact (C) epicardial layer and a noncompacted (NC) endocardial layer of prominent trabeculations and deep intertrabecular recesses. The maximal end-diastolic ratio of noncompacted to compacted wall was \> 2.3 measured by MRI. The patients had no systemic hypertension.

We used two established control cohorts \[[@CIT0033]\]. The control cohort A comprised 320 Caucasian sex-matched unrelated individuals without cardiomyopathy (who had preserved EF \> 55% and no ventricular dilatation and hypertrophy as shown by echocardiography and ventriculography and/or angiography). All of these individuals were older than 50 years (in order to exclude late onset cardiomyopathy). The second control cohort B included 192 Caucasian sex-matched blood donors from the local blood transfusion service without heart disease. None of the control individuals was hypertensive.

![DNA sequencing electropherograms demonstrating heterozygosity for the six detected *NEBL* mutations. The missense mutations are shown as two overlapping peaks (marked with an arrow). Codons are marked with gray blocks](AMS-12-27358-g005){#F0005}

Genetic analysis {#S20016}
----------------

A bioinformatic approach for detected variants was used which was based on presence or absence of these in population-based databases. First, we searched dbSNP (build 135, at <http://www.ncbi.nlm.nih.gov/snp>), which also includes data from the 1000 Genomes project. Second, we searched the Exome Variant Server (EVS) provided by the Exome Sequencing Project (ESP) of the National Heart, Lung and Blood Institute (<http://evs.gs.washington.edu/EVS/>, Tennessen *et al*. \[[@CIT0034]\]). The EVS data release ESP5400 is taken from 5379 samples drawn from multiple ESP cohorts and represents the first data freeze of the ESP exome variant data (EVS release version: v.0.0.12). The ESP dataset includes exome data for 3510 individuals of European descent, which matched our patients. Third, we performed mutation prediction by the two most widely used analysis tools to predict the possible impact of an amino acid substitution. PolyPhen2 analysis was performed through the portal <http://genetics.bwh.harvard.edu/pph2/> \[[@CIT0035]\]. Mutation Taster analysis was performed through the portal <http://www.mutationtaster.org> \[[@CIT0036]\].

Supplemental results {#S0017}
====================

Clinical features {#S20018}
-----------------

Proband II-3 of family B, carrier of mutation p.I652L, had severe hypertrophy (IVS 32 mm, PWT 16 mm) which progressed into thinning of the septum (IVS 26 mm), followed by dilatation (LVEDD from 43 to 62 mm) and reduction of EF (from 58% to 26%) over a period of about 20 years. Therefore, she underwent heart transplantation at the age of 46 years. This "end-stage" HCM patient showed LV chamber dilatation with diffuse transmural fibrous replacement in the ventricular septum and LV free wall ([Supplemental Figures S2A](#F0006){ref-type="fig"} and [S2B](#F0006){ref-type="fig"}). Histopathological features of HCM such as myocyte hypertrophy and myocyte disarray were present in her heart ([Supplemental Figures S2C](#F0006){ref-type="fig"}) as well as extensive replacement fibrosis and myocyte vacuolization (Supporting Figure S2D).

![Heart removed at transplantation of a HCM patient with *NEBL* mutation (proband B: II-2 of family B). **A** -- Apical transverse section of the heart showing dilatation of the left ventricular (LV) and thinning of the septum and ventricular free wall; whitish areas (arrows) are indicative of septal scarring. **B** -- Long-axis LV section (atria missing due to transplantation). Subaortic outflow tract obstruction with endocardial fibrous plaque (arrow). **C** -- Histology of right ventricle (RV) showing myocyte hypertrophy and disarray; hematoxylin eosin stain, 160×. **D** -- Histology of the septum with extensive replacement fibrosis and myocyte vacuolization; Azan-Mallory stain 200×](AMS-12-27358-g006){#F0006}

Cardiac MRI of proband II-1 of family G, carrier of mutation p.P916L, revealed LVNC affecting the entire apical region as well as the mid-segments of the lateral and anterolateral wall (7 segments in 17-segment model) ([Supplemental Figure S3](#F0007){ref-type="fig"}). The maximal NC/C ratio was 3.8. The left ventricle was severely dilated (LVEDD 66 mm, LVESD 53 mm), with severely reduced EF (30%). Due to multiple episodes of non-sustained ventricular tachycardia, an ICD was implanted at the age of 43 years.

![Magnetic resonance imaging of the heart of the LVNC patient with *NEBL* mutation (proband G:II-1 of family G). ECG retrogated SSFP movie sequence (trufi) was used to assess ventricular function on a 1.5T Siemens Avanto instrument. **A** -- Diastolic four-chamber view shows significant LVNC (arrow) affecting the entire apical region as well as the mid-segment of the lateral wall. **B** -- Short axis images show significant LVNC (arrows) affecting the entire apical region as well as the mid-segments of the lateral and anterolateral wall](AMS-12-27358-g007){#F0007}

Further detected variants in NEBL {#S20019}
---------------------------------

We identified 14 single nucleotide variants including five synonymous and nine non-synonymous variants ([Supplemental Table SI](#T0003){ref-type="table"}). All of these were detected in the cardiomyopathy cohorts in different frequencies (from 1% to 31%) and were represented in dbSNP except for one. Two of these variants, p.K60N and p.G202R, were recently described by Purevjav *et al*. in two adult DCM patients \[[@CIT0037]\]. To validate our results, we analyzed a second independent control group (cohort B) in addition to control cohort A (1024 control alleles in total). We detected the variant p.K60N in five HCM patients (frequency 2.3%). Subsequent evaluation in the two control cohorts A and B revealed p.K60N in 14 subjects (frequency 2.7%) including one with homozygous genotype. The variant p.G202R was identified in one HCM patient (frequency 0.5%). Analysis of the two control cohorts revealed four individuals carrying the heterozygous variant (frequency 0.8%). A search of the ESP data showed that p.K60N and p.G202R are present in allele frequencies of 0.31% and 1.08%, respectively.

###### 

Detected variants in the coding region of *NEBL*

  DNA change   AA change   Exon   Variant   Known/novel   dbSNP ID      Reference
  ------------ ----------- ------ --------- ------------- ------------- --------------------------
  c.109T\>C    p.L37L      2      sSNP      Known         rs140734883   --
  c.180G\>C    p.K60N      3      nsSNP     Known         rs41277374    Purevjav *et al*. (2010)
  c.191A\>G    p.K64R      3      nsSNP     Known         rs71578975    --
  c.489T\>C    p.Y163Y     6      sSNP      Known         rs141153708   --
  c.604G\>A    p.G202R     7      nsSNP     Known         rs137973321   Purevjav *et al*. (2010)
  c.1051A\>G   p.M351V     11     nsSNP     Known         rs4025981     Arimura *et al*. (2000)
  c.1132G\>C   p.D378H     12     nsSNP     Known         rs41277370    --
  c.1672A\>C   p.R558R     17     sSNP      Novel         --            --
  c.1861A\>G   p.I621V     18     nsSNP     Known         rs79718972    --
  c.1962T\>A   p.N654K     19     nsSNP     Known         rs4748728     Arimura *et al*. (2000)
  c.2031G\>A   p.R677R     20     sSNP      Known         rs1006363     --
  c.2182A\>G   p.T728A     22     nsSNP     Known         rs71535732    Arimura *et al*. (2000)
  c.2654C\>T   p.S885F     26     nsSNP     Known         rs143584663   --
  c.2997A\>G   p.T999T     28     sSNP      Known         rs2296614     --

AA -- amino acid, sSNP -- synonymous SNP, nsSNP -- non-synonymous SNP, dbSNP ID -- SNP database (build 135) identifier.
